- Marionville mayor ‘kind of agreed’ with Kansas City shooter’s views
- Rev. Al Sharpton’s Easter message: Politically ‘crucified’ Obama has risen again
- Supreme Court to weigh challenge to ban on campaign lies
- UNICEF launches ‘Mr. Poo’ mascot in India to curb public defecation
- Teen taking selfie by train: ‘Wow, that guy just kicked me in the head’
- Goodbye, Afghanistan — hello, Africa: Air Force to shift as U.S. exits Middle East
- Iran mulls ban on vasectomies, decrease on abortions to bolster population
- CNN op-ed claims right-wingers ‘more deadly than jihadists’
- Classes resume at high school rocked by stabbings
- ABC News accuses Center for Public Integrity of stealing Pulitzer-winning work
FDA expands approval of J&J prostate cancer drug
WASHINGTON (AP) - The Food and Drug Administration on Monday expanded approval of Johnson & Johnson’s prostate cancer pill Zytiga for men with an earlier stage of the disease.
The agency says Zytiga is now approved for late-stage prostate cancer patients who have not yet received chemotherapy, based on study results showing it can extend life by up to five months when taken by men in that group.
The FDA previously approved the drug in April 2011 for men with prostate cancer who have already taken the chemotherapy drug docetaxel.
Zytiga works by decreasing the male hormone testosterone. Testosterone stimulates the growth of prostate tumors, and treatment often includes drugs aimed at cutting the body’s testosterone production. While older drugs can block about 90 percent of the hormone, scientists say Zytiga blocks virtually all of it, which can help slow the disease.
The FDA approved the new indication based on a J&J study of 1,088 men with late-stage prostate cancer who had not already received chemotherapy.
The typical patient taking Zytiga survived five months longer than the typical patient taking a fake pill, or placebo.
When the study was stopped, the median time until cancer worsened in the group getting dummy pills was about eight months. Those on Zytiga were faring much better, so researchers could not yet report how long it would take their cancers to worsen.
FDA cancer drugs chief Dr. Richard Pazdur said the FDA’s approval “provides patients and health care providers the option of using Zytiga earlier in the course of treatment.”
Common side effects with the drug include fatigue, joint swelling, diarrhea, vomiting, cough and shortness of breath.
Shares of Johnson & Johnson rose 10 cents to $70.55 in afternoon trading Monday.
TWT Video Picks
By John R. Bolton
Reality calls for attaching Gaza to Egypt and the West Bank to Jordan
- 'Culture of intimidation' seen in Nevada ranch standoff
- IRS emails reveal discussion with Justice about suing nonprofits for election activities
- Rand and Ron Paul ride to the rescue for Bundy in Nevada standoff with feds
- Nevada Bundy ranch standoff could leave dirt on Harry Reid reputation
- Eric Cantor rejects latest Obama immigration outreach
- GOP writes legislation to deny Attorney General Eric Holder his salary
- CNN op-ed claims right-wingers 'more deadly than jihadists'
- U.S. Navy to turn seawater into jet fuel
- WEBER: Obamacare cuts home healthcare for millions of seniors
- Army goes to war with National Guard, seizes Apache attack helicopters
Celebrity deaths in 2014
Top 10 handguns in the U.S.